✦ LIBER ✦

Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?

✍ Scribed by Twelves, C J; Cassidy, J

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluating coagulation disorders in the

✍ Zeki Ustuner, O. Meltem Akay, Muge Keskin, Esin Kuş, Cengiz Bal, Zafer Gulbas 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 181 KB

Should carcinoembryonic antigen be used

✍ Luis A. Carriquiry; Alberto Piñeyro 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 967 KB

Which source should we use to measure qu

✍ E. M. le Coq; A. J. P. Boeke; P. D. Bezemer; V. T. Colland; J. Th. M. van Eijk 📂 Article 📅 2000 🏛 Springer Netherlands 🌐 English ⚖ 114 KB

The MMP-9 expression determined the effi

✍ Yutaka Ogata; Keiko Matono; Teruo Sasatomi; Nobuya Ishibashi; Akira Ohkita; Tomo 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 311 KB

The use of tumour markers CEA, CA-195 an

✍ Ward, U; Primrose, JN; Finan, PJ; Perren, TJ; Selby, P; Purves, DA; Cooper, EH 📂 Article 📅 1993 🏛 Nature Publishing Group 🌐 English ⚖ 751 KB

CEA tissue staining in colorectal cancer

✍ Giuseppe Midiri; Claudio Amanti; Marco Benedetti; Costantino Campisi; Giuseppe S 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 821 KB